Olmesartán/Hidroclorotiazida Combix (Olmesartan Medoxomil, Hydrochlorothiazide)

Olmesartan Medoxomil/Hydrochlorothiazide is used in the management of high blood pressure through combined renin‑angiotensin blockade and diuresis.

• Hypertension: improves blood pressure control when monotherapy is insufficient.
• Heart failure with reduced ejection fraction: assists in volume management and afterload reduction as part of guideline‑directed therapy.
• Diabetic nephropathy: helps slow progression of renal impairment by lowering systemic pressure.
• Post‑myocardial infarction hypertension: supports secondary prevention by maintaining target pressures.
• Chronic kidney disease stage 3–4: contributes to proteinuria reduction and pressure control.
• Resistant hypertension: provides an additional mechanism when other agents have failed.

• Olmesartan Medoxomil selectively blocks the angiotensin II type 1 (AT1) receptor, preventing vasoconstriction and aldosterone release. Hydrochlorothiazide inhibits sodium‑chloride reabsorption in the distal convoluted tubule, promoting natriuresis and diuresis. The combination yields additive blood‑pressure reduction by decreasing peripheral resistance and plasma volume.

Adverse reactions may vary in frequency and severity.

Common Side Effects

• Dizziness or light‑headedness
• Headache
• Fatigue
• Increased urination
• Electrolyte disturbances (e.g., low potassium)
• Mild gastrointestinal discomfort

Serious or Rare Side Effects

• Severe hypotension
• Acute kidney injury
• Hyperkalemia or severe electrolyte imbalance
• Angio‑edema
• Liver function abnormalities
• Blood dyscrasias such as agranulocytosis

Before starting therapy, clinicians should evaluate patient history and monitor relevant parameters.

• Renal function: assess baseline creatinine and eGFR, adjust if impaired.
• Electrolytes: monitor potassium and sodium levels regularly.
• Pregnancy: contraindicated in the second and third trimesters; avoid unless benefits outweigh risks.
• Concomitant drugs: review for potential additive potassium‑sparing effects.
• Gout: use cautiously in patients with a history of hyperuricemia.
• Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Olmesartan/Hydrochlorothiazide may interact with several drug classes; monitoring is advised.

Major Interactions (Avoid)

• Aliskiren (combined renin‑angiotensin inhibition may cause renal impairment).
• Potassium‑sparing diuretics or supplements (risk of hyperkalemia).
• Lithium (increased lithium levels and toxicity).

Moderate Interactions (Monitor Closely)

• Non‑steroidal anti‑inflammatory drugs (NSAIDs) (may reduce antihypertensive effect and affect renal function).
• ACE inhibitors or other ARBs (additive hypotensive effect).
• Antidiabetic agents (enhanced glucose‑lowering effect, risk of hypoglycaemia).